Prothena CorpPRTA
About: Prothena Corp PLC is a clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. The company's clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson's disease and other related synucleinopathies (PRX002), and inflammatory diseases, including ATTR amyloidosis [Coramitug (PRX004)], Alzheimer's disease (PRX123), Neurodegeneration (PRXPRX019), and Others.
Employees: 163
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
126% more first-time investments, than exits
New positions opened: 52 | Existing positions closed: 23
27% more call options, than puts
Call options by funds: $4.37M | Put options by funds: $3.43M
27% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 41
15% more funds holding
Funds holding: 159 [Q1] → 183 (+24) [Q2]
0% more funds holding in top 10
Funds holding in top 10: 3 [Q1] → 3 (+0) [Q2]
19.73% less ownership
Funds ownership: 97.07% [Q1] → 77.35% (-19.73%) [Q2]
61% less capital invested
Capital invested by funds: $647M [Q1] → $253M (-$394M) [Q2]
Research analyst outlook
7 Wall Street Analysts provided 1 year price targets over the past 3 months
7 analyst ratings
RBC Capital Brian Abrahams | 19%upside $10 | Sector Perform Maintained | 5 Aug 2025 |
HC Wainwright & Co. Andrew S. Fein | 67%upside $14 | Buy Reiterated | 5 Aug 2025 |
Chardan Capital Rudy Li | 115%upside $18 | Buy Maintained | 5 Aug 2025 |
B of A Securities Tazeen Ahmad | 52%downside $4 | Underperform Downgraded | 28 May 2025 |
Piper Sandler Yasmeen Rahimi | 867%upside $81 | Overweight Maintained | 27 May 2025 |
Financial journalist opinion
Based on 5 articles about PRTA published over the past 30 days









